Physician

General Surgery

Dr. Erwin Kruger, MD

Erwin Kruger, MD practices General Surgery. Erwin Kruger is a published doctor as well. He has 20 publications published. The latest was: In Vitro Mineralization of Human Mesenchymal Stem Cells on Three-Dimensional Type I Collagen versus PLGA Scaffolds: A Comparative Analysis.

Publications

TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
Approaches to preclinical screening of antiangiogenic agents.
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
In Vitro Mineralization of Human Mesenchymal Stem Cells on Three-Dimensional Type I Collagen versus PLGA Scaffolds: A Comparative Analysis.
Extracellular-signal-related kinase 1/2 is responsible for inhibition of osteogenesis in three-dimensional cultured MC3T3-E1 cells.
The role of therapeutic angiogenesis in tissue repair and regeneration.
Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-...
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

Doctors Specialties

General Surgery

Accepted Insurances

Education

UCLA Medical Center

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Dennis P. Thompson, MD This Doctor is OpenDoctor Recommended.
	Dr. Eugene D. Gierson, MD
	Dr. Anthony Shaw, MD This Doctor is OpenDoctor Recommended.
	Dr. Darin J. Saltzman, MD This Doctor is OpenDoctor Recommended.
	Dr. Jesse E. Thompson, MD This Doctor is OpenDoctor Recommended.
	Dr. Melinda A. Gibbons, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kenneth K. Kao, MD This Doctor is OpenDoctor Recommended.
	Dr. Mia E. Miller, MD This Doctor is OpenDoctor Recommended.